新诊断2级IDH突变胶质瘤对比增强的预后意义
该回顾性研究纳入2010至2021年两家机构325例新诊断2级IDH突变胶质瘤患者,评估术前MRI瘤内对比增强与生存的关系。中位随访10.5年,16%患者存在术前增强,单因素和多因素分析均未发现增强与总生存或无进展生存相关。结论提示术前增强本身不应妨碍符合条件患者考虑vorasidenib。
要点
- 2级IDH突变胶质瘤术前对比增强不提示更差的总生存或无进展生存。
- 增强特征如可测量大小或边界清晰与否,均与总生存无关。
- 术前增强本身不应作为排除vorasidenib的依据。
核心结论
- 在2级IDH突变胶质瘤中,术前对比增强与总生存和无进展生存均无显著关联。
- 术前增强不能识别该人群中的高危亚组,其存在本身不应妨碍符合条件患者考虑vorasidenib。
研究设计与样本
- 回顾性队列研究,纳入2010至2021年两家机构连续治疗的325例新诊断2级IDH突变胶质瘤患者。
- 术前MRI由两名独立阅片者评估瘤内增强,第三阅片者裁决分歧。
- 采用Kaplan-Meier分析、单因素和多因素Cox回归评估总生存和无进展生存。
主要发现
- 325例可评估患者中位年龄37岁,47%存在1p/19q共缺失,35%实现全切除。
- 中位随访10.5年,53例(16%)存在术前增强,其中72%为不可测量增强、62%边界不清。
- 87%的患者术后无残留增强。
临床怎么用
- 对于新诊断2级IDH突变胶质瘤,术前对比增强不应单独用于判断预后或排除vorasidenib治疗。
- 临床决策应综合其他预后因素,而非仅依据术前增强的存在与否。
局限性
- 回顾性研究设计,可能存在选择偏倚和未测量混杂因素。
- 术前增强患者比例较低(16%),可能限制亚组分析的统计效力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Contrast enhancement is generally considered an adverse prognostic feature in adult glioma. However, its significance in newly diagnosed grade 2 IDH-mutant glioma remains uncertain, with important implications for use of the mutant IDH inhibitor vorasidenib. We evaluated survival outcomes associated with preoperative enhancement in this population. METHODS: We retrospectively evaluated consecutive patients with grade 2 IDH-mutant glioma treated at two institutions between 2010 and 2021. Preoperative MRIs were assessed for intratumoral enhancement by two independent readers with third-reader adjudication. Overall survival (OS) and progression-free survival (PFS) were evaluated by Kaplan-Meier analysis, univariate and multivariable Cox regression. RESULTS: Among 325 evaluable patients, median age was 37 years, 47% had 1p/19q-codeletion, and 35% had gross-total resection. Median follow-up was 10.5 years. Preoperative enhancement was observed in 53 (16%) patients, most commonly nonmeasurable (72%) or ill-defined (62%); most (87%) had no residual postoperative enhancement. Preoperative enhancement was not associated with OS or PFS in either univariate analyses (OS HR 1.16 [0.67-2.01], p = 0.591; PFS HR 1.25 [0.88-1.80], p = 0.216) or multivariable analyses adjusting for established prognostic factors (OS HR 0.86 [0.46-1.61], p = 0.633; PFS HR 1.29 [0.86-1.92], p = 0.219). Enhancement characteristics (measurable size, well-defined morphology) were not associated with OS. CONCLUSION: In grade 2 IDH-mutant glioma, preoperative enhancement was not associated with OS or PFS. These findings suggest that preoperative enhancement does not identify a higher-risk subgroup in this population, and that its presence alone should not preclude consideration of vorasidenib in eligible patients. Neuro-Oncologists often view contrast enhancement on a brain MRI as a sign that a tumor is more aggressive. However, it is unclear whether this is true for people with newly diagnosed grade 2 IDH-mutant glioma, a slow-growing type of brain tumor. We studied 325 patients treated at two hospitals and found that contrast enhancement before surgery was not linked to survival or to tumor progression, including after accounting for other important variables. These findings suggest that contrast enhancement alone before surgery should not determine treatment decisions, and may help guide the use of the targeted therapy vorasidenib.
引用
- Nakhate V, Lasica AB, Aker L, et al. Prognostic Significance of Contrast Enhancement in Newly Diagnosed Grade 2 IDH-mutant Glioma. Neuro Oncol. 2026. PMID: 42886524. doi:10.1093/neuonc/noag262
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。